Guggenheim Reiterates Buy Rating on AMLX
Guggenheim maintains its buy rating on AMLX with a $40 price target, a 116.86% upside from the current price.
Key Points
- Guggenheim reiterated its buy rating on AMLX, setting a $40 price target as of June 25, 2026.
- Guggenheim's $40 price target implies 116.86% upside from Amylyx Pharmaceuticals, Inc.'s ($AMLX) current $18.45 share price.
- AMLX shares traded near $16.94 on Thursday, with notable insider buying activity reported in June.
- Institutional investors like FMR LLC and Janus Henderson Group adjusted their AMLX holdings recently.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Guggenheim has reiterated its buy rating on AMLX, setting a price target of $40. This update came on June 25, 2026, as analyst Seamus Fernandez continues to see potential in the stock.
Other Institutional Activity in AMLX
FMR LLC slightly increased its holdings in AMLX by 112,122 shares, bringing its total to 16,630,541 shares valued at approximately $231.16 million, marking a 0.7% increase. Meanwhile, BlackRock, Inc. reduced its stake by 225,595 shares, now holding 8,828,836 shares worth around $122.72 million, a 2.5% decrease. Janus Henderson Group PLC significantly boosted its position by 520,201 shares, resulting in a total of 4,986,073 shares valued at $69.26 million, reflecting an 11.6% increase.
Amylyx Pharmaceuticals, Inc. Stock Down 46.9%
Shares of AMLX traded near $16.94 on Thursday. The stock has seen various institutional movements, which may affect its future performance. Investors are keeping an eye on these changes as they could impact AMLX's market dynamics.
$AMLX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Amylyx Pharmaceuticals, Inc.
Recent insider activity at AMLX includes several purchases. On June 4, 2026, insiders like George Milne Jr., Daphne Quimi, and Karen Firestone each acquired 24,372 shares. Additionally, on May 21, 2026, Karen Firestone purchased 3,800 shares at an average price of $13.51.
Analysts Set New Price Targets
On June 25, 2026, Guggenheim maintained its buy rating on AMLX with a $40 price target. Earlier, on April 28, 2026, Mizuho also maintained a buy rating, setting a target of $21. The consensus among analysts remains positive, with a general buy recommendation and a variety of price targets reflecting different levels of optimism.
Bottom Line
Guggenheim's reiterated buy rating and $40 price target show confidence in AMLX's potential. Investors will be watching institutional and insider activities for further signals. Remember, 13F filings and analyst ratings offer insights but are not current positions or advice.
Get Amylyx Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $AMLX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.